Molecular Partners (NASDAQ:MOLN – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.02, FiscalAI reports.
Molecular Partners Price Performance
Shares of MOLN stock opened at $4.40 on Tuesday. The business has a fifty day simple moving average of $4.03 and a 200 day simple moving average of $4.23. The company has a market cap of $177.65 million, a P/E ratio of -2.27 and a beta of 1.08. Molecular Partners has a twelve month low of $3.53 and a twelve month high of $5.36.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on MOLN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a report on Wednesday, July 8th. HC Wainwright reissued a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Molecular Partners has a consensus rating of “Hold” and a consensus target price of $8.38.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors and hedge funds.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.
Further Reading
- Five stocks we like better than Molecular Partners
- Beyond Big Tech: 3 Non-Tech Earnings Winners to Watch
- 3 Contrarian Trades for a Market That Looks Too Hot
- The Bull Case for D-Wave After a Disappointing Earnings Season
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
